Utilidad pronóstica del PET/CT en cáncer de páncreas

Background: Pancreatic cancer is the tenth most prevalent cancer in world, and represents the fourth cause of cancer death. It has a five year-survival of 5%. Aim: To assess the prognostic value of PET/CT in pancreatic cancer. Material and Methods: Sixty-nine patients with pancreatic adenocarcino...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Guevara,David Ladrón de, Pavez,Gonzalo, Zapata,Jaime, Romero,Claudio, Tapia,Valezka, Buckel,Erwin, Ferrario,Mario
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2018
Materias:	Carcinoma Pancreatic Ductal Computed Tomography Medical Oncology Pancreatic Neoplasm Positron Emission Tomography
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872018000400413
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872018000400413
record_format	dspace
spelling	oai:scielo:S0034-988720180004004132018-07-03Utilidad pronóstica del PET/CT en cáncer de páncreasGuevara,David Ladrón dePavez,GonzaloZapata,JaimeRomero,ClaudioTapia,ValezkaBuckel,ErwinFerrario,Mario Carcinoma Pancreatic Ductal Computed Tomography Medical Oncology Pancreatic Neoplasm Positron Emission Tomography Background: Pancreatic cancer is the tenth most prevalent cancer in world, and represents the fourth cause of cancer death. It has a five year-survival of 5%. Aim: To assess the prognostic value of PET/CT in pancreatic cancer. Material and Methods: Sixty-nine patients with pancreatic adenocarcinoma who underwent staging 18F-fluorodeoxyglucose (FDG) PET/CT between December 2008 and July 2016 were selected. Gender, age, body-mass index, laboratory tests (Ca 19-9, hemoglobin, erythrocyte sedimentation rate, liver enzymes, lactate dehydrogenase), histological differentiation of tumor, American Joint Committee on Cancer (AJCC) stage, size and 18F-FDG uptake (maximal stan-dardized uptake value [SUVmax]) of the primary tumor, nodal involvement and distant metastasis detected by PET/CT were registered. Survival was assessed using Kaplan-Meier curves, Log Rank test and Cox multivariable analysis. Results: Mortality was 66.7%, during a mean observation time of 18 months (range 20 days-66 months). Curative surgery, lack of metastases detected by PET/CT, histologically well differentiated tumors, and SUVmax ≤ 4.3 were significantly associated with a better specific survival, determined by the Log Rank test. Histological differentiation was the only variable that had a statistically significant prognostic value in the multivariable analysis. Conclusions: The detection of distant metastases and the intensity of primary tumor 18F-FDG uptake during PET/CT provide useful prognostic information in pancreatic cancer patients.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.146 n.4 20182018-04-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872018000400413es10.4067/s0034-98872018000400413
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Carcinoma Pancreatic Ductal Computed Tomography Medical Oncology Pancreatic Neoplasm Positron Emission Tomography
spellingShingle	Carcinoma Pancreatic Ductal Computed Tomography Medical Oncology Pancreatic Neoplasm Positron Emission Tomography Guevara,David Ladrón de Pavez,Gonzalo Zapata,Jaime Romero,Claudio Tapia,Valezka Buckel,Erwin Ferrario,Mario Utilidad pronóstica del PET/CT en cáncer de páncreas
description	Background: Pancreatic cancer is the tenth most prevalent cancer in world, and represents the fourth cause of cancer death. It has a five year-survival of 5%. Aim: To assess the prognostic value of PET/CT in pancreatic cancer. Material and Methods: Sixty-nine patients with pancreatic adenocarcinoma who underwent staging 18F-fluorodeoxyglucose (FDG) PET/CT between December 2008 and July 2016 were selected. Gender, age, body-mass index, laboratory tests (Ca 19-9, hemoglobin, erythrocyte sedimentation rate, liver enzymes, lactate dehydrogenase), histological differentiation of tumor, American Joint Committee on Cancer (AJCC) stage, size and 18F-FDG uptake (maximal stan-dardized uptake value [SUVmax]) of the primary tumor, nodal involvement and distant metastasis detected by PET/CT were registered. Survival was assessed using Kaplan-Meier curves, Log Rank test and Cox multivariable analysis. Results: Mortality was 66.7%, during a mean observation time of 18 months (range 20 days-66 months). Curative surgery, lack of metastases detected by PET/CT, histologically well differentiated tumors, and SUVmax ≤ 4.3 were significantly associated with a better specific survival, determined by the Log Rank test. Histological differentiation was the only variable that had a statistically significant prognostic value in the multivariable analysis. Conclusions: The detection of distant metastases and the intensity of primary tumor 18F-FDG uptake during PET/CT provide useful prognostic information in pancreatic cancer patients.
author	Guevara,David Ladrón de Pavez,Gonzalo Zapata,Jaime Romero,Claudio Tapia,Valezka Buckel,Erwin Ferrario,Mario
author_facet	Guevara,David Ladrón de Pavez,Gonzalo Zapata,Jaime Romero,Claudio Tapia,Valezka Buckel,Erwin Ferrario,Mario
author_sort	Guevara,David Ladrón de
title	Utilidad pronóstica del PET/CT en cáncer de páncreas
title_short	Utilidad pronóstica del PET/CT en cáncer de páncreas
title_full	Utilidad pronóstica del PET/CT en cáncer de páncreas
title_fullStr	Utilidad pronóstica del PET/CT en cáncer de páncreas
title_full_unstemmed	Utilidad pronóstica del PET/CT en cáncer de páncreas
title_sort	utilidad pronóstica del pet/ct en cáncer de páncreas
publisher	Sociedad Médica de Santiago
publishDate	2018
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872018000400413
work_keys_str_mv	AT guevaradavidladronde utilidadpronosticadelpetctencancerdepancreas AT pavezgonzalo utilidadpronosticadelpetctencancerdepancreas AT zapatajaime utilidadpronosticadelpetctencancerdepancreas AT romeroclaudio utilidadpronosticadelpetctencancerdepancreas AT tapiavalezka utilidadpronosticadelpetctencancerdepancreas AT buckelerwin utilidadpronosticadelpetctencancerdepancreas AT ferrariomario utilidadpronosticadelpetctencancerdepancreas
_version_	1718436999226982400

Utilidad pronóstica del PET/CT en cáncer de páncreas

Ejemplares similares